First-in-class therapy approved to treat agitation linked to Alzheimer’s disease, addressing a major unmet need for patients and caregivers.
Phase 3 Trials | 04/05/2026 | By News Bureau
Lupin Completes Phase 3 Trials for Lucentis Biosimilar
Lupin has successfully completed a global Phase 3 clinical study of LUBT010, its biosimilar candidate to Lucentis.
Phase 3 Trials | 06/08/2024 | By Aishwarya | 674
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy